DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy

DTX@VTX NPs synergize PD-L1 nanoinhibitor BMS-1 NPs to reshape the immunosuppressive tumour microenvironment for increasing M1-like cells and CD8 T cells, decreasing M2-like cells and MDSCs and killing tumour cells.